Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the insulin receptor and of the insulin-like growth factor 1 receptor (IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis.

CAS：867160-71-2
中文别名：顺式-3-[8-氨基-1-(2-苯基-7-喹啉基)咪唑并[1,5-A]吡嗪-3-基]-1-甲基环丁醇;
英文别名：Kinome_3532;Linsitinib;cis-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-1-yl]-1-methylcyclobutan-1-ol;OSI-906 (Linsitinib);cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol;cis-3-[8-amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol;OSI-906AA;OSI906;
分子式：C26H23N5O
分子量：421.494
精确质量：421.19
Psa：89.33
Logp：5.4033

MDL号：MFCD12912153

密度：1.39 g/cm3